Market Overview:
The global carvedilol market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of hypertension and congestive heart failure (CHF), increasing awareness about carvedilol, and growing demand for generic drugs. However, the high cost of branded drugs is expected to restrain the growth of the global carvedilol market during the forecast period. Based on type, the global carvedilol market can be segmented into tablet and capsule. The tablet segment is expected to dominate the global carvedilol market duringthe forecast period owingto its lower price as compared with capsules.
Product Definition:
It is a beta blocker used to treat high blood pressure and congestive heart failure.
Tablet:
Tablet is a form of oral solid dosage drug delivery which is administered to patients suffering from cardiovascular diseases, respiratory disorders and diabetes. The tablet consists of an inert core containing the active ingredient along with a coating that disintegrates when placed in water or another solvent. The rapid increase in the geriatric population across the globe has led to increased demand for tablets due to their ability to provide quick relief from chronic conditions such as pain, stiffness and swelling associated with old age.
Capsule:
A capsule is a small container made up of gelatin, sugar, and oil. It is used for the packaging of drugs to protect them from contamination & light and to deliver the drug in an appropriate amount. The size of capsules ranges from 2-3 millimeters to 10-12 millimeters; they are produced in various shapes including round, flat-faced, oblong, etc.
Application Insights:
The primary hypertension segment dominated the global carvedilol market in 2017 and is expected to maintain its dominance over the forecast period. The growing prevalence of hypertension coupled with rising demand for effective treatment options is anticipated to drive this application segment.
Carvedilol has been proven effective in treating both systolic and diastolic forms of hypertension, thus making it one of the most preferred drugs across all major applications segments. Furthermore, a large body of clinical evidence indicates that carvedilol is superior compared to other beta-blockers in treating essential Hypertension as well as moderate/severe heart failure, which further boosts its demand across various applications.
On the other hand, CHF held a significant share within overall market revenue in 2017 owing to wide usage as an anti-arrhythmic agent.
Regional Analysis:
North America dominated the global carvedilol market in 2017. High prevalence of primary hypertension, CHF, and other cardiac diseases is anticipated to drive the demand for carvedilol in this region. In addition, increasing awareness about various treatment options and favorable government initiatives are expected to fuel growth over the forecast period. For instance, as per a recent study published by National Center for Biotechnology Information (NCBI), around 30 million people suffer from heart failure in U.S., with an average of around 1 million new cases annually being diagnosed which results into increased mortality rate due to heart failure or sudden cardiac death (U.S.).
The Asia Pacific region is projected to witness lucrative CAGR over the coming years owing to high unmet clinical needs coupled with rapidly improving healthcare infrastructure especially in developing countries such as India.
Growth Factors:
- Increasing prevalence of heart failure: The global prevalence of heart failure is expected to increase from 26 million in 2011 to over 40 million by 2030. This will create a large pool of patients who will require treatment, including those for whom carvedilol may be an appropriate therapy.
- Growing awareness and diagnosis of heart failure: There is growing awareness among both physicians and patients about the symptoms and risk factors for heart failure, which is helping to drive earlier diagnosis and treatment of the condition. This should lead to increased use of carvedilol in the years ahead.
- Availability of generic formulations: Carvedilol is available as a generic drug in many countries, which helps make it more affordable for patients than some other therapies for heart failure. As more competitors enter the market, this should help keep prices low and encourage wider use of carvedilol overall.
Scope Of The Report
Report Attributes
Report Details
Report Title
Carvedilol Market Research Report
By Type
Tablet, Capsule
By Application
Primary Hypertension, Congestive Heart Failure (CHF), Left Ventricular Dysfunction, Other
By Companies
Qilu Pharmaceutical, Roche, Cipla, Ningbo Tianheng Pharmaceutical, Apotex INC, Aurobindo Pharma, BEXIMCO USA, Teva, Mylan, TARO, Qilu Pharmaceutical, Zydus Pharms, Lupin, Sandoz, Glenmark Generics, DR Reddy's Labs, Chartwell Molecular
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
229
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Carvedilol Market Report Segments:
The global Carvedilol market is segmented on the basis of:
Types
Tablet, Capsule
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Primary Hypertension, Congestive Heart Failure (CHF), Left Ventricular Dysfunction, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Qilu Pharmaceutical
- Roche
- Cipla
- Ningbo Tianheng Pharmaceutical
- Apotex INC
- Aurobindo Pharma
- BEXIMCO USA
- Teva
- Mylan
- TARO
- Qilu Pharmaceutical
- Zydus Pharms
- Lupin
- Sandoz
- Glenmark Generics
- DR Reddy's Labs
- Chartwell Molecular
Highlights of The Carvedilol Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tablet
- Capsule
- By Application:
- Primary Hypertension
- Congestive Heart Failure (CHF)
- Left Ventricular Dysfunction
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Carvedilol Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Carvedilol is a beta-blocker medication that is used to treat high blood pressure, heart failure, and other conditions. It works by reducing the amount of blood that flows through your veins.
Some of the key players operating in the carvedilol market are Qilu Pharmaceutical, Roche, Cipla, Ningbo Tianheng Pharmaceutical, Apotex INC, Aurobindo Pharma, BEXIMCO USA, Teva, Mylan, TARO, Qilu Pharmaceutical, Zydus Pharms, Lupin, Sandoz, Glenmark Generics, DR Reddy's Labs, Chartwell Molecular.
The carvedilol market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Carvedilol Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Carvedilol Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Carvedilol Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Carvedilol Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Carvedilol Market Size & Forecast, 2018-2028 4.5.1 Carvedilol Market Size and Y-o-Y Growth 4.5.2 Carvedilol Market Absolute $ Opportunity
Chapter 5 Global Carvedilol Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Carvedilol Market Size Forecast by Type
5.2.1 Tablet
5.2.2 Capsule
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Carvedilol Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Carvedilol Market Size Forecast by Applications
6.2.1 Primary Hypertension
6.2.2 Congestive Heart Failure (CHF)
6.2.3 Left Ventricular Dysfunction
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Carvedilol Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Carvedilol Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Carvedilol Analysis and Forecast
9.1 Introduction
9.2 North America Carvedilol Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Carvedilol Market Size Forecast by Type
9.6.1 Tablet
9.6.2 Capsule
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Carvedilol Market Size Forecast by Applications
9.10.1 Primary Hypertension
9.10.2 Congestive Heart Failure (CHF)
9.10.3 Left Ventricular Dysfunction
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Carvedilol Analysis and Forecast
10.1 Introduction
10.2 Europe Carvedilol Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Carvedilol Market Size Forecast by Type
10.6.1 Tablet
10.6.2 Capsule
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Carvedilol Market Size Forecast by Applications
10.10.1 Primary Hypertension
10.10.2 Congestive Heart Failure (CHF)
10.10.3 Left Ventricular Dysfunction
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Carvedilol Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Carvedilol Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Carvedilol Market Size Forecast by Type
11.6.1 Tablet
11.6.2 Capsule
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Carvedilol Market Size Forecast by Applications
11.10.1 Primary Hypertension
11.10.2 Congestive Heart Failure (CHF)
11.10.3 Left Ventricular Dysfunction
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Carvedilol Analysis and Forecast
12.1 Introduction
12.2 Latin America Carvedilol Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Carvedilol Market Size Forecast by Type
12.6.1 Tablet
12.6.2 Capsule
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Carvedilol Market Size Forecast by Applications
12.10.1 Primary Hypertension
12.10.2 Congestive Heart Failure (CHF)
12.10.3 Left Ventricular Dysfunction
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Carvedilol Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Carvedilol Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Carvedilol Market Size Forecast by Type
13.6.1 Tablet
13.6.2 Capsule
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Carvedilol Market Size Forecast by Applications
13.10.1 Primary Hypertension
13.10.2 Congestive Heart Failure (CHF)
13.10.3 Left Ventricular Dysfunction
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Carvedilol Market: Competitive Dashboard
14.2 Global Carvedilol Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Qilu Pharmaceutical
14.3.2 Roche
14.3.3 Cipla
14.3.4 Ningbo Tianheng Pharmaceutical
14.3.5 Apotex INC
14.3.6 Aurobindo Pharma
14.3.7 BEXIMCO USA
14.3.8 Teva
14.3.9 Mylan
14.3.10 TARO
14.3.11 Qilu Pharmaceutical
14.3.12 Zydus Pharms
14.3.13 Lupin
14.3.14 Sandoz
14.3.15 Glenmark Generics
14.3.16 DR Reddy's Labs
14.3.17 Chartwell Molecular